Carmustine has been evaluated across numerous clinical trials spanning Phase 1, Phase 2, and Phase 3, primarily targeting central nervous system malignancies—including glioblastoma and anaplastic astrocytoma—as well as relapsed or refractory malignant lymphomas and multiple myeloma. Sponsored by academic institutions, medical centers, cooperative oncology groups, and pharmaceutical corporations, these studies demonstrate varied recruitment statuses, including completed, active, recruiting, terminated, and withdrawn.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05521984 | RECRUITING | Pediatric Brain Tumor; Pediatric Solid Tumor |
Washington University School of Medicine |
2023-04-03 | PHASE1 |
| NCT04871607 | RECRUITING | Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma |
City of Hope Medical Center |
2021-11-02 | PHASE2 |
| NCT04222062 | RECRUITING | Brain Tumor - Metastatic |
University of Nebraska |
2020-11-06 | PHASE2 |
| NCT07774299 | NOT_YET_RECRUITING | DLBCL |
Ruijin Hospital |
2026-08-25 | PHASE2 |
| NCT06687772 | RECRUITING | Diffuse Large B Cell Lymphoma |
Washington University School of Medicine |
2025-01-16 | PHASE2 |
| NCT07199296 | RECRUITING | Mantle Cell Lymphoma (MCL) |
Ruijin Hospital |
2025-07-01 | PHASE2 |
| NCT05083754 | RECRUITING | Glioblastoma Multiforme |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2022-08-31 | PHASE1 |
| NCT06692452 | WITHDRAWN | Lymphoma; Peripheral T Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma |
Eric Jacobsen, MD |
2024-12-24 | PHASE2 |
| NCT01840566 | ACTIVE_NOT_RECRUITING | Non-Hodgkin's Lymphoma |
Memorial Sloan Kettering Cancer Center |
2013-04 | PHASE1 |
| NCT06915246 | RECRUITING | Lymphoma; Non-Hodgkin Lymphoma; Hodgkin Lymphoma |
VIVUS LLC |
2025-03-12 | PHASE2 |
| NCT04728633 | ACTIVE_NOT_RECRUITING | Metastatic Malignant Neoplasm in the Liver; Metastatic Uveal Melanoma; Stage IV Choroidal and Ciliary Body Melanoma AJCC V8 |
Thomas Jefferson University |
2021-09-27 | PHASE2 |
| NCT06652165 | NOT_YET_RECRUITING | DLBCL |
Ruijin Hospital |
2024-11-01 | PHASE2 |
| NCT02570542 | ACTIVE_NOT_RECRUITING | Diffuse Large B-cell Lymphoma (DLBCL); Relapsed Diffuse Large B-cell Lymphoma (DLBCL); Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
Memorial Sloan Kettering Cancer Center |
2015-10 | PHASE2 |
| NCT06377540 | RECRUITING | Autologous Stem Cell Transplant; Classic Hodgkin Lymphoma |
Masonic Cancer Center, University of Minnesota |
2024-12-04 | PHASE2 |
| NCT05052957 | RECRUITING | Glioblastoma Multiforme; Glioblastoma Multiforme, Adult; Supratentorial Glioblastoma; Supratentorial Gliosarcoma |
Leland Metheny |
2023-01-20 | PHASE2 |
| NCT00641381 | COMPLETED | Lymphoma |
City of Hope Medical Center |
2000-05-10 | PHASE1 |
| NCT05931263 | RECRUITING | Newly Diagnosed Peripheral T-cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2023-06-01 | PHASE3 |
| NCT05814718 | UNKNOWN | Autologous Stem Cell Transplantation; Conditioning |
First Affiliated Hospital Xi'an Jiaotong University |
2023-04-15 | |
| NCT05466318 | UNKNOWN | Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell |
Sichuan University |
2022-07-01 | PHASE3 |
| NCT00716066 | ACTIVE_NOT_RECRUITING | Autoimmune Disease; Neurologic Autoimmune Disease; Autologous Transplant Autoimmune; Multiple Sclerosis Transplant; MS Stem Cell Transplant; Multiple Sclerosis Stem Cell Transplant; Stiff Person Syndrome; HCT for Neurologic Autoimmune Disorders; CIDP Transplant; Myasthenia Gravis Transplant; Autoimmune Nervous System Disorder; Central Nervous System Vasculitis; Cerebellar Degeneration; Chronic Inflammatory Demyelinating Polyneuropathy; Lambert Eaton Myasthenic Syndrome; Myasthenia Gravis; Neuromyelitis Optica; Opsoclonus Myoclonus Syndrome; Rasmussen Subacute Encephalitis |
Fred Hutchinson Cancer Center |
2008-06 | PHASE2 |
| NCT05228249 | WITHDRAWN | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma |
Fred Hutchinson Cancer Center |
2023-04 | PHASE1 |
| NCT03382977 | TERMINATED | Glioblastoma Multiforme |
VBI Vaccines Inc. |
2017-12-06 | PHASE1; PHASE2 |
| NCT05863845 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2023-06-01 | |
| NCT02443077 | ACTIVE_NOT_RECRUITING | Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type |
National Cancer Institute (NCI) |
2016-10-12 | PHASE3 |
| NCT05367856 | UNKNOWN | T Cell Lymphoma |
Ruijin Hospital |
2022-05-28 | PHASE2 |
| NCT03570983 | UNKNOWN | Multiple Myeloma |
Swedish Medical Center |
2018-09-05 | PHASE2 |
| NCT03736616 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Swedish Medical Center |
2019-08-16 | PHASE2 |
| NCT04421378 | TERMINATED | Glioblastoma Multiforme |
Karyopharm Therapeutics Inc |
2020-06-08 | PHASE1; PHASE2 |
| NCT03583424 | COMPLETED | Hematopoietic Cell Transplantation Recipient; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Transformed Indolent Non-Hodgkin Lymphoma |
Ohio State University Comprehensive Cancer Center |
2018-09-10 | PHASE1; PHASE2 |
| NCT03019640 | COMPLETED | Mantle Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Indolent Adult Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Indolent Adult Non-Hodgkin Lymphoma |
M.D. Anderson Cancer Center |
2017-10-10 | PHASE2 |
| NCT01476839 | COMPLETED | Recurrent Adult Hodgkin Lymphoma |
City of Hope Medical Center |
2012-11-09 | PHASE1 |
| NCT02797470 | ACTIVE_NOT_RECRUITING | HIV Infection; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Plasmablastic Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Burkitt Lymphoma; Recurrent Follicular Lymphoma; Stage III Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Follicular Lymphoma; Stage IV Mantle Cell Lymphoma |
AIDS Malignancy Consortium |
2016-06-23 | PHASE1; PHASE2 |
| NCT03072771 | COMPLETED | Diffuse Large B Cell Lymphoma |
Washington University School of Medicine |
2017-08-01 | PHASE1 |
| NCT00712582 | COMPLETED | Non-Hodgkin's Lymphoma |
Memorial Sloan Kettering Cancer Center |
2008-07-01 | PHASE2 |
| NCT01511562 | ACTIVE_NOT_RECRUITING | Lymphoma |
Alliance for Clinical Trials in Oncology |
2012-09 | PHASE2 |
| NCT02670109 | UNKNOWN | Triple-Negative Invasive Breast Carcinoma; Residual Tumor |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2018-02-01 | PHASE2 |
| NCT02342782 | COMPLETED | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma |
City of Hope Medical Center |
2020-06-08 | PHASE1 |
| NCT02504359 | COMPLETED | Plasma Cell Leukemia; Recurrent Plasma Cell Myeloma |
OHSU Knight Cancer Institute |
2015-07-20 | PHASE1 |
| NCT02343666 | WITHDRAWN | Human Immunodeficiency Virus 1 Positive; Stage I Adult Hodgkin Lymphoma; Stage I Adult Non-Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult Non-Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Non-Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Non-Hodgkin Lymphoma |
Fred Hutchinson Cancer Center |
2016-08-15 | PHASE1 |
| NCT00968760 | COMPLETED | Lymphoma; B-cell Lymphoma |
M.D. Anderson Cancer Center |
2011-06-20 | PHASE1 |
| NCT00591630 | COMPLETED | Diffuse Large Cell Lymphoma; Lymphoma |
M.D. Anderson Cancer Center |
2007-11-14 | PHASE2 |
| NCT02059239 | COMPLETED | Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma |
Weill Medical College of Cornell University |
2014-06-04 | PHASE1; PHASE2 |
| NCT02483000 | TERMINATED | Burkitt Lymphoma; CD20-Positive Neoplastic Cells Present; Diffuse Large B-Cell Lymphoma; Indolent Non-Hodgkin Lymphoma; Mantle Cell Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory Mature B-Cell Non-Hodgkin Lymphoma |
Fred Hutchinson Cancer Center |
2017-02-01 | PHASE1 |
| NCT00569985 | COMPLETED | Lymphoma |
City of Hope Medical Center |
2007-06 | PHASE1 |
| NCT03579927 | WITHDRAWN | CD19 Positive; Mantle Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma |
M.D. Anderson Cancer Center |
2019-10-03 | PHASE1; PHASE2 |
| NCT02329080 | COMPLETED | Diffuse Large B-cell Lymphoma |
International Extranodal Lymphoma Study Group (IELSG) |
2014-12 | PHASE2 |
| NCT00345865 | COMPLETED | Lymphoma |
Masonic Cancer Center, University of Minnesota |
2005-08-24 | PHASE2 |
| NCT02896582 | COMPLETED | Mantle Cell Lymphoma |
The Lymphoma Academic Research Organisation |
2016-11-29 | PHASE2 |
| NCT01769911 | WITHDRAWN | Adult Nasal Type Extranodal NK/T-cell Lymphoma; AIDS-related Diffuse Large Cell Lymphoma; AIDS-related Diffuse Mixed Cell Lymphoma; AIDS-related Diffuse Small Cleaved Cell Lymphoma; AIDS-related Immunoblastic Large Cell Lymphoma; AIDS-related Lymphoblastic Lymphoma; AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Small Noncleaved Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; HIV-associated Hodgkin Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I AIDS-related Lymphoma; Stage II AIDS-related Lymphoma; Stage III AIDS-related Lymphoma; Stage IV AIDS-related Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenström Macroglobulinemia |
Fred Hutchinson Cancer Center |
2015-02 | |
| NCT00536601 | COMPLETED | Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Burkitt Lymphoma; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET); Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Plasma Cell Neoplasm; Primary Systemic Amyloidosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Neuroblastoma; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Regional Neuroblastoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific; Waldenström Macroglobulinemia |
Roswell Park Cancer Institute |
2006-06-29 | |
| NCT00669669 | TERMINATED | Glioblastoma; Gliosarcoma |
Fred Hutchinson Cancer Center |
2009-02-25 | PHASE1; PHASE2 |
| NCT01008462 | COMPLETED | B-Cell Prolymphocytic Leukemia; Hypodiploidy; Loss of Chromosome 17p; Plasma Cell Leukemia; Progression of Multiple Myeloma or Plasma Cell Leukemia; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Childhood Hodgkin Lymphoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Small Lymphocytic Lymphoma; t(14;16); t(4;14); T-Cell Prolymphocytic Leukemia; Waldenstrom Macroglobulinemia |
Fred Hutchinson Cancer Center |
2010-03-18 | PHASE2 |
| NCT00439556 | COMPLETED | CD20 Positive; Hematopoietic and Lymphoid Cell Neoplasm; Lymphocytic Neoplasm; Lymphoma |
M.D. Anderson Cancer Center |
2007-02-13 | PHASE2 |
| NCT01035463 | COMPLETED | Anaplastic Large Cell Lymphoma, ALK-Negative; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma |
University of Nebraska |
2009-11-12 | PHASE1; PHASE2 |
| NCT01921387 | COMPLETED | Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Hodgkin Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma |
Fred Hutchinson Cancer Center |
2013-10-09 | PHASE1; PHASE2 |
| NCT00695409 | COMPLETED | Lymphoma |
City of Hope Medical Center |
2008-03-18 | PHASE2 |
| NCT02348255 | WITHDRAWN | Adult Brain Glioblastoma; Recurrent Adult Brain Neoplasm |
University of California, Davis |
2016-01 | PHASE2 |
| NCT02366663 | TERMINATED | Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma |
City of Hope Medical Center |
2015-01 | PHASE3 |
| NCT00920153 | TERMINATED | Lymphoma |
French Innovative Leukemia Organisation |
2008-05 | PHASE3 |
| NCT00005803 | COMPLETED | Prolymphocytic Leukemia; Recurrent Adult Hodgkin Lymphoma; Recurrent Childhood Hodgkin Lymphoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Non-Hodgkin Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Small Lymphocytic Lymphoma; T-Cell Chronic Lymphocytic Leukemia; T-Cell Prolymphocytic Leukemia |
Fred Hutchinson Cancer Center |
1999-09 | PHASE1; PHASE2 |
| NCT03315520 | Unknown status | Relapsed/Refractory Malignant Lymphomas |
State Budgetary Healthcare Institution National Medical Surgical Center N.A. N.I. Pirogov Ministry of Health of Russia |
2016-01-22 | Phase 2 |
| NCT00795665 | COMPLETED | Glioma |
University of California, Davis |
2008-06 | PHASE2 |
| NCT00288626 | COMPLETED | Relapsing-Remitting Multiple Sclerosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-07 | PHASE2 |
| NCT01969435 | COMPLETED | Hodgkin Disease; Lymphoma, Non-Hodgkin |
Washington University School of Medicine |
2014-03-19 | PHASE2 |
| NCT00992446 | COMPLETED | Adult Diffuse Large B-Cell Lymphoma; B-Cell Non-Hodgkin Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Non-Hodgkin Lymphoma; T-Cell Non-Hodgkin Lymphoma |
Fred Hutchinson Cancer Center |
2010-09-02 | PHASE2 |
| NCT01310868 | COMPLETED | Glioblastoma |
University College, London |
2011-05 | PHASE2 |
| NCT00571493 | COMPLETED | Non-hodgkin's Lymphoma; Mantle Cell Lymphoma |
University of Nebraska |
2006-04-14 | PHASE1; PHASE2 |
| NCT00233987 | COMPLETED | Lymphoma |
SWOG Cancer Research Network |
2005-10 | PHASE2 |
| NCT01692691 | TERMINATED | Melanoma Metastatic |
Western Regional Medical Center |
2012-08 | PHASE2 |
| NCT01656980 | UNKNOWN | Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Glioblastoma |
Shandong Lanjin Pharmaceuticals Co.,Ltd |
2012-08 | PHASE3 |
| NCT00908180 | UNKNOWN | Lymphoma |
Cancer Research UK |
2009-07 | PHASE2 |
| NCT00632827 | TERMINATED | Peripheral T-Cell Lymphoma |
University of California, San Francisco |
2008-07-01 | PHASE2 |
| NCT00691015 | COMPLETED | Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms |
Barbara Ann Karmanos Cancer Institute |
2008-05 | PHASE2 |
| NCT00317408 | UNKNOWN | Lymphoma |
European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma |
2004-04 | |
| NCT01500161 | TERMINATED | Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Hodgkins Disease; Non-Hodgkins Lymphoma; Aplastic Anemia; Multiple Myeloma; Myelodysplastic Syndrome |
Texas Oncology Cancer Center |
2011-11 | PHASE2 |
| NCT01653418 | TERMINATED | Multiple Myeloma |
Washington University School of Medicine |
2012-09 | PHASE2 |
| NCT00521014 | COMPLETED | Lymphoma |
Memorial Sloan Kettering Cancer Center |
2007-10 | PHASE2 |
| NCT01637753 | UNKNOWN | Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Glioblastoma |
Shandong Lanjin Pharmaceuticals Co.,Ltd |
2012-06 | |
| NCT01656980 | Unknown status | Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma |
Shandong Lanjin Pharmaceuticals Co.Ltd |
2012-08 | Phase 3 |
| NCT00472056 | COMPLETED | Lymphoma |
M.D. Anderson Cancer Center |
2005-03 | PHASE2 |
| NCT01637753 | Unknown status | Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma |
Shandong Lanjin Pharmaceuticals Co.Ltd |
2012-06 | Not Applicable |
| NCT00961220 | COMPLETED | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7; Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7 |
National Cancer Institute (NCI) |
2010-02-01 | PHASE1; PHASE2 |
| NCT00761280 | TERMINATED | Anaplastic Astrocytoma; Glioblastoma |
Isarna Therapeutics GmbH |
2008-12 | PHASE3 |
| NCT00002766 | COMPLETED | Leukemia; Lymphoma |
Memorial Sloan Kettering Cancer Center |
1996-03 | PHASE3 |
| NCT00559104 | COMPLETED | Lymphoma |
City of Hope Medical Center |
1998-10 | PHASE2 |
| NCT00814593 | WITHDRAWN | Brain and Central Nervous System Tumors |
Lisata Therapeutics, Inc. |
2008-11 | PHASE2 |
| NCT00574080 | TERMINATED | Multiple Myeloma |
University of Arkansas |
2006-07 | PHASE3 |
| NCT00720447 | UNKNOWN | Lymphoma |
Cancer Research UK |
2008-11 | PHASE2 |
| NCT01220297 | TERMINATED | Hematologic Diseases; Acute-graft-versus-host Disease; Leukemia; Non-Hodgkin Lymphoma (NHL); Hodgkin Lymphoma |
Stanford University |
2006-08 | PHASE2 |
| NCT00723658 | WITHDRAWN | Lymphoma |
SWOG Cancer Research Network |
2008-09 | PHASE2 |
| NCT00482053 | TERMINATED | Lymphoma, B-cell; Lymphoma, Non-Hodgkin; Diffuse Large B-cell Lymphoma (DLBCL); Malignant Lymphoma, Non-Hodgkin |
Stanford University |
2006-10 | PHASE2 |
| NCT00003631 | COMPLETED | Lymphoma |
Memorial Sloan Kettering Cancer Center |
1998-08 | PHASE2 |
| NCT00244946 | COMPLETED | Lymphoma |
Barbara Ann Karmanos Cancer Institute |
2004-03 | PHASE1 |
| NCT00349778 | COMPLETED | Multiple Myeloma |
Stanford University |
2006-08 | PHASE2 |
| NCT00004031 | COMPLETED | Lymphoma |
SWOG Cancer Research Network |
1997-07 | PHASE3 |
| NCT00388349 | COMPLETED | Hodgkin Disease; Hodgkin's Lymphoma; Lymphoma |
Stanford University |
2001-09 | PHASE2 |
| NCT00281879 | TERMINATED | Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unusual Cancers of Childhood |
OHSU Knight Cancer Institute |
2006-02 | PHASE2 |
| NCT00544570 | COMPLETED | Lymphoma |
City of Hope Medical Center |
1998-04 | |
| NCT00242996 | COMPLETED | Lymphoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2004-03 | PHASE2 |
| NCT00076986 | COMPLETED | Glioblastoma Multiforme |
INSYS Therapeutics Inc |
2004-02 | PHASE3 |
| NCT00005985 | COMPLETED | Lymphoma |
Masonic Cancer Center, University of Minnesota |
2000-08 | PHASE2 |
| NCT00003567 | TERMINATED | Brain and Central Nervous System Tumors; Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific |
Case Comprehensive Cancer Center |
1999-05 | PHASE1 |
| NCT00020943 | COMPLETED | Lymphoma |
Alliance for Clinical Trials in Oncology |
2001-06 | PHASE2 |
| NCT00027612 | COMPLETED | Brain and Central Nervous System Tumors |
Alliance for Clinical Trials in Oncology |
2002-07 | PHASE1; PHASE2 |
| NCT00002676 | COMPLETED | Lymphoma |
Alliance for Clinical Trials in Oncology |
1995-07 | PHASE2 |
| NCT00060255 | COMPLETED | Breast Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Testicular Germ Cell Tumor; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific |
Roswell Park Cancer Institute |
1991-12 | PHASE2 |
| NCT00052923 | COMPLETED | Lymphoma |
Eastern Cooperative Oncology Group |
2003-03 | PHASE3 |
| NCT00058292 | COMPLETED | Lymphoma |
Northwestern University |
2000-04 | PHASE1 |
| NCT00003613 | TERMINATED | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma |
National Cancer Institute (NCI) |
1999-04 | PHASE1 |
| NCT00017147 | COMPLETED | Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System |
SWOG Cancer Research Network |
2001-09 | PHASE3 |
| NCT00002836 | COMPLETED | Breast Cancer |
M.D. Anderson Cancer Center |
1995-09-26 | PHASE3 |
| NCT00086879 | COMPLETED | Brain and Central Nervous System Tumors |
European Organisation for Research and Treatment of Cancer - EORTC |
2004-05 | PHASE2 |
| NCT00003765 | COMPLETED | Brain and Central Nervous System Tumors |
National Cancer Institute (NCI) |
1999-05 | PHASE1 |
| NCT00002556 | COMPLETED | Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
National Cancer Institute (NCI) |
1994-07 | PHASE3 |
| NCT00005961 | COMPLETED | Melanoma (Skin) |
National Cancer Institute (NCI) |
2000-06 | PHASE2 |
| NCT00080886 | COMPLETED | Lymphoma |
University of Nebraska |
2002-05-08 | PHASE2 |
| NCT00002982 | COMPLETED | Lymphoma |
Memorial Sloan Kettering Cancer Center |
1997-01 | PHASE2 |
| NCT00006695 | COMPLETED | Lymphoma |
University of Nebraska |
2000-04-01 | PHASE2 |
| NCT00003632 | COMPLETED | Lymphoma |
Memorial Sloan Kettering Cancer Center |
1998-09 | PHASE2 |
| NCT00070187 | COMPLETED | Lymphoma |
Children's Oncology Group |
2003-11 | PHASE2; PHASE3 |
| NCT00005090 | TERMINATED | Lymphoma |
SWOG Cancer Research Network |
2000-04 | PHASE3 |
| NCT00003727 | COMPLETED | Leukemia |
University of Maryland, Baltimore |
1999-03 | PHASE2 |
| NCT00028665 | COMPLETED | Lymphoma |
Case Comprehensive Cancer Center |
2000-06 | PHASE2 |
| NCT00007982 | COMPLETED | Brain and Central Nervous System Tumors; Head and Neck Cancer; Lymphoma |
Herbert Irving Comprehensive Cancer Center |
1999-04 | PHASE2 |
| NCT00003621 | COMPLETED | Brain and Central Nervous System Tumors |
Alliance for Clinical Trials in Oncology |
1999-02 | PHASE2 |
| NCT00002545 | COMPLETED | Brain and Central Nervous System Tumors |
Radiation Therapy Oncology Group |
1994-02 | PHASE3 |
| NCT00046852 | COMPLETED | Infection; Multiple Myeloma and Plasma Cell Neoplasm |
University of Maryland, Baltimore |
2001-12 | PHASE1; PHASE2 |
| NCT00006386 | COMPLETED | Brain and Central Nervous System Tumors |
Radiation Therapy Oncology Group |
2001-03 | PHASE2 |
| NCT00014573 | COMPLETED | Brain and Central Nervous System Tumors |
Barbara Ann Karmanos Cancer Institute |
1998-08 | PHASE2 |
| NCT00276809 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2001-06 | PHASE2 |
| NCT00004072 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Case Comprehensive Cancer Center |
1999-09 | PHASE2 |
| NCT00045721 | TERMINATED | Brain and Central Nervous System Tumors |
Pediatric Brain Tumor Consortium |
2003-03 | PHASE1 |
| NCT00003417 | COMPLETED | Brain and Central Nervous System Tumors |
Radiation Therapy Oncology Group |
1998-09 | PHASE1; PHASE2 |
| NCT00002986 | COMPLETED | Brain and Central Nervous System Tumors |
Duke University |
1997-02 | PHASE1 |
| NCT00002835 | COMPLETED | Lymphoma |
M.D. Anderson Cancer Center |
1995-10-30 | PHASE3 |
| NCT00002772 | TERMINATED | Breast Cancer |
SWOG Cancer Research Network |
1996-07 | PHASE3 |
| NCT00003484 | COMPLETED | Brain and Central Nervous System Tumors; Neuroblastoma |
Darell D. Bigner, MD, PhD |
1997-09 | PHASE1 |
| NCT00005981 | COMPLETED | Colorectal Cancer |
Case Comprehensive Cancer Center |
2000-06 | PHASE2 |
| NCT00002548 | COMPLETED | Multiple Myeloma |
SWOG Cancer Research Network |
1994-01 | PHASE3 |
| NCT00005987 | TERMINATED | Multiple Myeloma and Plasma Cell Neoplasm |
Masonic Cancer Center, University of Minnesota |
2000-08 | PHASE2 |
| NCT00005637 | COMPLETED | Brain and Central Nervous System Tumors |
Memorial Sloan Kettering Cancer Center |
1999-12 | PHASE1 |
| NCT00005998 | WITHDRAWN | Lymphoma |
Masonic Cancer Center, University of Minnesota |
2000-01 | PHASE2 |
| NCT00006747 | COMPLETED | Graft Versus Host Disease; Lymphoma |
Alliance for Clinical Trials in Oncology |
2000-11 | PHASE2 |
| NCT00003346 | COMPLETED | Melanoma (Skin) |
Memorial Sloan Kettering Cancer Center |
1997-11 | PHASE2 |
| NCT00003397 | COMPLETED | Lymphoma |
University of Maryland, Baltimore |
1998-09 | PHASE2 |
| NCT00003402 | COMPLETED | Leukemia; Lymphoma |
University of Maryland, Baltimore |
1999-01 | PHASE2 |
| NCT00002941 | COMPLETED | Lymphoma |
Children's Oncology Group |
1998-04 | PHASE2 |
| NCT00003401 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
University of Maryland, Baltimore |
1999-01 | PHASE2 |
| NCT00003399 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
University of Maryland, Baltimore |
1998-09 | PHASE2 |
| NCT00003543 | COMPLETED | Colorectal Cancer |
Memorial Sloan Kettering Cancer Center |
1998-06 | PHASE1 |
| NCT00003463 | COMPLETED | Brain and Central Nervous System Tumors |
Duke University |
1998-07 | PHASE1 |
| NCT00007852 | COMPLETED | Lymphoma |
University of Nebraska |
2000-09-01 | PHASE2 |
| NCT00003176 | COMPLETED | Brain and Central Nervous System Tumors |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
1998-03-25 | PHASE2 |
| NCT00002719 | COMPLETED | Leukemia; Neutropenia |
European Organisation for Research and Treatment of Cancer - EORTC |
1995-12 | PHASE3 |
| NCT00002552 | COMPLETED | Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm |
Barbara Ann Karmanos Cancer Institute |
1993-10 | PHASE2 |
| NCT00005066 | COMPLETED | Sarcoma |
University of Chicago |
2000-06 | PHASE2 |
| NCT00003996 | COMPLETED | Brain and Central Nervous System Tumors |
Alliance for Clinical Trials in Oncology |
1999-05 | PHASE2 |
| NCT00005081 | COMPLETED | Brain and Central Nervous System Tumors |
Duke University |
2000-08 | PHASE2 |
| NCT00003413 | COMPLETED | Ovarian Cancer |
University of Maryland, Baltimore |
1998-09 | PHASE2 |
| NCT00002988 | COMPLETED | Brain and Central Nervous System Tumors |
Duke University |
1997-04 | PHASE1 |
| NCT00003348 | COMPLETED | Brain and Central Nervous System Tumors |
Duke University |
1998-05 | PHASE1 |
| NCT00006123 | WITHDRAWN | Breast Cancer |
Beth Israel Deaconess Medical Center |
2000-07 | PHASE1; PHASE2 |
| NCT00002604 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
Case Comprehensive Cancer Center |
1996-01 | PHASE1 |
| NCT00002620 | COMPLETED | Brain and Central Nervous System Tumors |
European Organisation for Research and Treatment of Cancer - EORTC |
1994-11 | PHASE3 |
| NCT00003400 | COMPLETED | Prostate Cancer |
University of Maryland, Baltimore |
1998-09 | PHASE2 |
| NCT03722355 | COMPLETED | Glioma; Glioblastoma Multiforme; Astrocytoma |
Radiation Therapy Oncology Group |
1990-11-09 | PHASE3 |
| NCT00002461 | COMPLETED | Lymphoma |
Montefiore Medical Center |
1988-04 | PHASE2 |
| NCT00016887 | UNKNOWN | Lymphoma |
German Low Grade Lymphoma Study Group |
2000-12 | PHASE3 |
| NCT00003578 | UNKNOWN | Lymphoma |
Lymphoma Trials Office |
1993-01 | PHASE3 |
| NCT00046878 | WITHDRAWN | Brain and Central Nervous System Tumors |
Duke University |
PHASE2 | |
| NCT00556127 | COMPLETED | Diffuse Large B-Cell Lymphoma; POOR PROGNOSIS |
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie |
2002-06 | PHASE2 |
| NCT00003467 | COMPLETED | Brain and Central Nervous System Tumors |
Duke University |
1998-01 | PHASE2 |
| NCT00003878 | COMPLETED | Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
New Approaches to Brain Tumor Therapy Consortium |
2002-04 | PHASE2 |
| NCT00002653 | UNKNOWN | Multiple Myeloma and Plasma Cell Neoplasm |
Medical Research Council |
1993-09 | PHASE3 |
| NCT00006656 | UNKNOWN | Brain and Central Nervous System Tumors |
Direct Therapeutics |
2000-06 | PHASE2 |
| NCT00003788 | UNKNOWN | Brain and Central Nervous System Tumors |
Colorado Health Foundation |
1998-04 | PHASE3 |
| NCT00009854 | UNKNOWN | Brain and Central Nervous System Tumors; Metastatic Cancer |
Direct Therapeutics |
2000-06 | PHASE1; PHASE2 |
| NCT00004028 | COMPLETED | Brain and Central Nervous System Tumors |
National Cancer Institute (NCI) |
1996-09 | PHASE1 |
| NCT00002599 | UNKNOWN | Multiple Myeloma and Plasma Cell Neoplasm |
Medical Research Council |
1994-09 | PHASE3 |
| NCT00005589 | COMPLETED | Lymphoma |
EBMT Solid Tumors Working Party |
1999-10 | PHASE3 |
| NCT00003876 | COMPLETED | Brain and Central Nervous System Tumors |
Barrett Cancer Center |
1999-04 | PHASE1 |
| NCT00005855 | COMPLETED | Brain and Central Nervous System Tumors |
New Approaches to Brain Tumor Therapy Consortium |
2000-07 | PHASE1; PHASE2 |
| NCT00275015 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
1998-01 | PHASE2 |
| NCT00003815 | UNKNOWN | Lymphoma |
Scotland and Newcastle Lymphoma Group |
1994-06 | PHASE3 |
| NCT00025636 | UNKNOWN | Lymphoma |
German Hodgkin's Lymphoma Study Group |
2001-07 | PHASE3 |
| NCT00004688 | COMPLETED | Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Mixed Gliomas; Glioblastoma Multiforme; Recurrent Brain Tumor |
Emory University |
1996-08 | PHASE2 |
| NCT00068952 | COMPLETED | Glioblastoma |
Pfizer |
2003-08 | PHASE3 |
| NCT00002638 | COMPLETED | Leukemia |
University of Nebraska |
1995-03 | PHASE2 |
| NCT00004892 | COMPLETED | Brain and Central Nervous System Tumors |
National Cancer Institute (NCI) |
2000-04 | PHASE1 |
| NCT00012051 | COMPLETED | Lymphoma |
Commissie Voor Klinisch Toegepast Onderzoek |
2000-09 | PHASE3 |
| NCT00669812 | UNKNOWN | Lymphoma; Small Intestine Cancer |
Cancer Research UK |
2008-02 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-06-10)
Check the
Carmustine
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.